My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AdvisorShares Psychedelics ETF (NY:PSIL)

19.18 +0.73 (+3.93%)

Streaming Delayed Price Updated: 10:55 AM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AdvisorShares Psychedelics ETF

< Previous 1 2 3 4 5 Next >

Why Did KTTA Stock Soar A Whopping 48% Today? ↗

Today 10:02 EST

The company announced the pricing of a public offering of 80 million shares of its common stock and said that the offering will extend its cash runway through at least the first half of 2028.

Via Stocktwits

NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition ↗

November 11, 2025

Via Stocktwits

Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug ↗

August 05, 2025

Quantum Biopharma's subsidiary, Huge Biopharma Australia, has cleared a regulatory milestone for its neuroprotective compound, Lucid-MS, in a Phase 1 trial.

Via Benzinga

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts ↗

June 23, 2025

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Via Stocktwits

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors ↗

May 24, 2025

Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.

Via Benzinga

Topics Government

5 ETFs That Beat Market Turmoil With Gains Last Week ↗

February 10, 2025

Last week had Wall Street facing volatility, tech earnings disappointments, mixed labor data, and rising inflation fears. Gold hit record highs.

Via Benzinga

Topics ETFs Economy

High-Momentum ETFs Leading the Market This Year

February 07, 2025

Momentum investors looking to start 2025 off on good footing might look no further than these high-flying ETFs, each of which has returned 14% or more in 2025.

Via MarketBeat

Topics ETFs

Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding ↗

January 29, 2025

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.

Via Stocktwits

Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish ↗

January 28, 2025

The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.

Via Stocktwits

5 Best-Performing Sector ETFs Of Q4 ↗

January 02, 2025

In this article, we have highlighted five top-performing ETFs from different sectors that were the leaders in the fourth quarter.

Via Talk Markets

Topics ETFs

Why Is Penny Stock Clearmind Gaining Today? ↗

December 24, 2024

Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder.

Via Benzinga

5 Best-Performing Sector ETFs Midway In Q4 ↗

November 16, 2024

In this article, we have highlighted five top-performing ETFs from different sectors that were the leaders over the past month.

Via Talk Markets

Topics ETFs

Top And Flop ETFs Of The First Half ↗

June 29, 2024

In this article, we have highlighted three ETFs each from the best and worst-performing zones in the first half of 2024.

Via Talk Markets

Topics ETFs

Best And Worst ETF Zones Of Q2 ↗

June 26, 2024

After the worst monthly decline in many months in April, global stock markets have staged a nice comeback on renewed Fed rate cut bets, ongoing artificial intelligence (AI) developments and strong...

Via Talk Markets

Topics Artificial Intelligence ETFs Economy

Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment ↗

June 05, 2024

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.

Via Benzinga

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗

April 17, 2024

Via Benzinga

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗

March 29, 2024

Via Benzinga

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗

March 20, 2024

Via Benzinga

Topics Economy

Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗

March 04, 2024

Via Benzinga

Mental Health Mavericks: 3 Stocks Changing the Game ↗

February 21, 2024

Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.

Via InvestorPlace

Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗

February 15, 2024

Via Benzinga

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗

January 27, 2024

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...

Via Benzinga

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗

January 12, 2024

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

Via Benzinga

Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗

January 07, 2024

Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury

Via Benzinga

Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗

December 27, 2023

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...

Via Benzinga

Psychedelic Drug Stocks Index Up In December; Down YTD ↗

December 27, 2023

The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021.

Via Talk Markets

Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗

December 18, 2023

Biden To Decide On Psychedelic Therapy Bill

Via Benzinga

Psychedelic Drug Stocks Index Declined 1.6% This Week ↗

December 17, 2023

Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD.

Via Talk Markets

Topics ETFs

Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More ↗

December 11, 2023

John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy

Via Benzinga

5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week ↗

December 10, 2023

The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week.

Via Talk Markets

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.